Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission
- PMID: 14716110
Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission
Abstract
We described a 41-year-old patient with acute promyelocytic leukemia (APL) who experienced two successive relapses: one after all-trans retinoic acid (ATRA) treatment and chemotherapy, and another after ATRA treatment and chemotherapy, followed by autologous peripheral blood stem cell transplantation. A third complete remission (CR) was achieved with arsenic trioxide (As2O3) therapy. Mini-transplantation was performed as consolidation therapy. While the patient was in molecular remission at the beginning of conditioning regimen, a new relapse arose after transplantation at time of cell recovery. This raises a potential relationship between relapse and the severe immunosuppression induced by mini-transplantation. To our knowledge, this is the first description of a mini-allograft in an APL patient achieving molecular remission after As2O3 therapy.
Similar articles
-
Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):545-7. J Pediatr Hematol Oncol. 1998. PMID: 9856675
-
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.Biol Blood Marrow Transplant. 2009 Nov;15(11):1479-84. doi: 10.1016/j.bbmt.2009.07.010. Epub 2009 Sep 1. Biol Blood Marrow Transplant. 2009. PMID: 19822309
-
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.Cancer. 2003 May 1;97(9):2218-24. doi: 10.1002/cncr.11314. Cancer. 2003. PMID: 12712474 Clinical Trial.
-
The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.J Biol Regul Homeost Agents. 1999 Oct-Dec;13(4):195-200. J Biol Regul Homeost Agents. 1999. PMID: 10703942 Review.
-
Treatment concepts of acute promyelocytic leukemia.Crit Rev Oncol Hematol. 2005 Nov;56(2):261-74. doi: 10.1016/j.critrevonc.2004.08.009. Epub 2005 Oct 19. Crit Rev Oncol Hematol. 2005. PMID: 16236522 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources